Noreen Roth Henig

Noreen Roth Henig, MD

Chief Medical Officer

Noreen Roth Henig, M.D. is an accomplished leader whose career spans clinical practice, academic medicine, translational science, clinical development, medical and regulatory affairs. She currently serves on the Board of Avidity Biosciences and most recently served as Chief Medical Officer of Breath Therapeutics, which was acquired by Zambon SpA in 2019. As CMO, Dr. Henig built and led the clinical team and was responsible for all development activities including clinical and non-clinical science, clinical operations, regulatory, project management, and medical affairs. Prior to joining Breath, Dr. Henig was Chief Medical Officer at ProQR Therapeutics where she brought two unique RNA oligonucleotides through early clinical trials in rare diseases. Before ProQR, Dr. Henig spent 2008 through 2014 at Gilead Sciences where she held roles with increasing responsibility, including building and leading a global medical affairs organization, strategic development of clinical trials Phase 2-4, regulatory strategy, corporate development, leadership of key alliances and commercial strategy. Prior to joining industry, Dr. Henig spent nearly 10 years in leadership roles within academic medicine at Stanford University and California Pacific Medical Center. She is a board-certified physician in Pulmonary, Critical Care and board eligible in Allergy and Immunology. Dr. Henig received her B.A. from Yale University and her M.D. from Albert Einstein College of Medicine of Yeshiva University in 1991 with a distinction in immunology. She trained in Internal Medicine at University of California, San Francisco and in Pulmonary/Critical Care and Allergy/Immunology at University of Washington, Seattle.